The report helps businesses gain a unique insight into the socio-economic dynamics, and helps analyze how they affect healthcare systems and their evolution. It can serve as a valuable tool with actionable guidance for sales, marketing, R&D and business managers with industry related interests.
Four chapters cover the numerical and written analysis for the following topics: Economic Outlook (38 Key industry indicators), The Healthcare System (HC system structures), Reforms (restructuring, re-engineering or austerity efforts) and the Healthcare Market (Capital Equipment, Medical Devices, Disposables and Pharmaceuticals).
The TforG report is accessible through a user friendly Business Intelligence tool. Licenses are valid for 1 year.
– Malaysia is one of the highest and steadiest performing nations economically in Asia, with an average annual GDP growth of near 6% in the last 50 years. Its current GDP growth is 4.2% (2016). It has the 4th largest market economy in Southeast Asia.
– In 2016, Malaysia recorded 61% of GDP for the import of goods and services, and 68% for exports.
– In February of 2016, inflation peaked to 4.1%, the steepest it has been since 2009. A tax on goods and services in the following month brought down the inflation to a more favourable rate, averaging 2.1% for the year in total.
– In 2016, €1.733 bn of the public budget was allocated to HC development.
– Malaysia plans to continue improving its infrastructure and to pursue international trade, public-private partnerships and manufacturing opportunities.
The Healthcare System:
– Malaysia has a strong healthcare structure, with a government-sponsored universal-coverage healthcare system. Healthcare indicators are higher than the regional averages, and public’s satisfaction with the healthcare provisions are relatively positive.
– Healthcare expenditure in Malaysia was €11.44 bn in 2016, equal to 4.31% of GDP. 55.1% of the total healthcare is funded publicly, and the remaining 44.9% stems from private sources (households, private insurance, etc.). 65% is spent on inpatient care and 32% is on outpatient care, and the remainder is represented by per diem cases.
– The Malaysian healthcare system is primarily financed through taxation designated for budgets allocated to the MOH by the Ministry of Finance. The Ministry of Health is the principle hospital financer, covering close to 50% of hospital expenses. The provision of inpatient care is largely provided for by the public sector (82%) and ambulatory care is for the majority part provided by the private sector (61%).
– The Medical Device Authority (MDA) regulates, monitors and licenses the medical devices in Malaysia, and the National Pharmaceutical Regulatory Agency (NPRA) regulates and monitors pharmaceuticals.
– Most of the primary care, dental care and retail pharmaceutical services in urban areas are currently provided by the private sector.
– Public primary care provision has not been able to keep up with the growth of urban areas, which gave the opportunity to the private sector to flourish. This resulted in those households that can afford it to seek primary care from private providers, whilst poorer households seek primary care in often crowded and understaffed public healthcare centers and clinics.
– Medical tourism is popular and the private sector along with the Malaysian government have a keen interest and ambition to continue expanding this sector in volume and quality to continue attracting foreign patients.
– Harmonized Medical Device Registration Framework (ongoing)
– Allied Health Professions Act 2016 (implementation 2017)
– 11th Malaysia Plan (2016-2020)
– Post-marketing guidelines (2015)
– Goods and Services Tax (GST) Act (2014)
– Medical Device Act (2013)
– 10th Malaysia Plan (2011-2015)
– The total expenditure on healthcare in 2016 was €11.44 bn; of this total, around 24.5% was spent on medical devices and equipment, and 26.2% was spent on pharmaceutical procurement.
– Varying between the high-end/state-of-the-art equipment to less complex medical devices, imports represent 75-90% of all medtech procured in Malaysia. From 2015 to 2016, medtech imports to Malaysia increased by close to 11%. Within this context, Singapore serves as a key transport hub for ASEAN countries.
– Due to lifestyle changes in the population and the resulting rise in non-communicable diseases (NCDs), the government is taking measures to have all healthcare facilities equipped with clinical equipment and tools for the assessment and management of NCDs. To this end, laboratories have been given increased investigative capacity.
– Malaysia is the largest exporter of rubber disposables worldwide.
– In order to participate in Malaysia’s public tendering process, a foreign supplier must collaborate with a registered Malaysian local/company.
– Malaysia’s government actively seeks to boost its domestic industry and wishes to encourage the growth of its domestic suppliers/distributors.
– The medical device market in Malaysia in 2016 was valued around €1.3 bn, with a strong year on year growth rate of around 8.5% until 2021.
– The vast majority of technologically high-end devices are imported; the largest importing nation being the USA.
– Improved import conditions and a stronger domestic economy will boost import volumes and value, as well as boost investor confidence.
– Malaysia provides extensive and capable manufacturing plants and a skilled workforce, as well as inexpensive land (in comparison to Western territories).
Includes tables centralizing all relevant data on socio-demographics, macroeconomics and national Healthcare.
National Care Provision data:
Provides an overview of the Healthcare demographics: Nation Care provision data, Intensive Care units, Operating rooms, Emergency Rooms, Hospital services, Healthcare professionals.
© TforG Group – All Rights Reserved.